Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Lung Cancer

Lung and bronchus cancer, the second most common form of cancer, accounts for 13.5% of all new cancer cases in the United States. In 2018 alone, lung cancer was newly diagnosed in 234,030 individuals and accounted for 154,050 deaths. In fact, lung cancer is the leading cause of cancer-related mortality in men and women, and is responsible for more than 25% of all cancer deaths. The 5-year survival rate for patients whose lung cancer has spread regionally (to regional lymph nodes) is 29.7%, but that survival rate is only 4.7% for patients with distant metastases.
Lung and bronchus cancer is the second most common form of cancer in the United States. In 2018, lung cancer was newly diagnosed in 234,030 individuals, representing 13.5% of all new cancer cases. Lung cancer remains the leading cause of cancer mortality in men and women, accounting for more than 25% of all cancer deaths, which translated to 154,050 deaths in 2018. The relative 5-year survival rate for metastatic lung cancer is only 4.7%.
For the second time this month, the FDA has given an approval to Genentech’s PD-L1 inhibitor, Tecentriq.
Brigatinib (Alunbrig), a new-­generation ALK inhibitor, significantly prolonged survival compared with standard of care with crizotinib (Xalkori) as first-line therapy in patients with advanced ALK-positive non–small-cell lung cancer (NSCLC). The median progression-free survival (PFS) was not reached in the brigatinib arm versus 9.8 months in the crizotinib arm. At 1 year, 67% of the patients who received brigatinib were still alive compared with 43% of patients who received crizotinib.

The FDA accelerated the approval of brigatinib (Alunbrig), a new generation of oral ALK inhibitor, for the treatment of patients with ALK-positive metastatic NSCLC who do not tolerate or have had an inadequate response to crizotinib..

Pemetrexed (Alimta) is a pyrrolopyrimidine-core folate analog metabolic inhibitor that disrupts the folate-dependent metabolic processes essential for cell replication. Pemetrexed exhibits its antineoplastic activity by inhibiting several key enzymes in the de novo synthesis of purine and pyrimidine nucleotides in neoplastic cells, resulting in cellular cytotoxicity.
What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.

In a study of more than 20,000 patients 65 and older with non–small cell lung cancer (NSCLC), treatment rates declined more in relation with increasing age than with the worsening of other illnesses.

The study, led by a team at the San Francisco VA Medical Center (SFVAMC) and University of California San Francisco (UCSF), found that for all stages of cancer, younger patients were more apt to receive treatment than older patients, regardless of general health and prognosis.

In a study of more than 20,000 patients 65 and older with non–small cell lung cancer (NSCLC), treatment rates declined more in relation with increasing age than with the worsening of other illnesses.

The study, led by a team at the San Francisco VA Medical Center (SFVAMC) and University of California San Francisco (UCSF), found that for all stages of cancer, younger patients were more apt to receive treatment than older patients, regardless of general health and prognosis.

Page 1 of 2
Results 1 - 10 of 18

The Journal of Hematology Oncology Pharmacy™| ISSN 2164-1153 (print); ISSN 2164-1161 (online)
©2019 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512